Fig. 3: MenACWY-specific serum bactericidal activity (rSBA) and ps-specific IgG and IgM responses following booster MenACWY-TT vaccination.

Data shown are for the booster cohort (n = 104), which includes only participants who received a MenACWY-TT booster vaccination at one year (1 y) post-primary vaccination. MenACWY-specific rSBA responses (A), corresponding percentages of participants with rSBA titers ≥8 and ≥128 (B), ps-specific IgG (C), and IgM (D) concentrations were assessed pre-booster (1 y), at one month (1 y + 1 m), and one year (1 y + 1 y) following booster vaccination. For reference, responses measured before and after primary vaccination in booster cohort participants are also shown. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) are shown in black, with error bars representing 95% confidence intervals. Following log10-transformation, rSBA and antibody responses were compared between timepoints using paired generalized linear mixed models (GLMM), followed by post-hoc Emmeans tests and subsequent Bonferroni correction for multiple testing. While statistical comparisons were performed across all timepoints, the significant p-values are only shown for the following comparisons: 1 y vs. 1 y + 1 m, 1 y vs. 1 y + 1 y, 1 m vs. 1 y + 1 m, 1 y + 1 m vs. 1 y + 1 y. Proportions of participants with rSBA ≥8 or ≥128 (with 95% CI) were calculated with the Wilson score interval with continuity correction.